β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression (original) (raw)

Nature volume 433, pages 73–77 (2005)Cite this article

Abstract

Glutamate is the principal excitatory neurotransmitter in the nervous system. Inactivation of synaptic glutamate is handled by the glutamate transporter GLT1 (also known as EAAT2; refs 1, 2), the physiologically dominant astroglial protein. In spite of its critical importance in normal and abnormal synaptic activity, no practical pharmaceutical can positively modulate this protein. Animal studies show that the protein is important for normal excitatory synaptic transmission, while its dysfunction is implicated in acute and chronic neurological disorders, including amyotrophic lateral sclerosis (ALS)3, stroke4, brain tumours5 and epilepsy6. Using a blinded screen of 1,040 FDA-approved drugs and nutritionals, we discovered that many β-lactam antibiotics are potent stimulators of GLT1 expression. Furthermore, this action appears to be mediated through increased transcription of the GLT1 gene7. β-Lactams and various semi-synthetic derivatives are potent antibiotics that act to inhibit bacterial synthetic pathways8. When delivered to animals, the β-lactam ceftriaxone increased both brain expression of GLT1 and its biochemical and functional activity. Glutamate transporters are important in preventing glutamate neurotoxicity1,9,10,11. Ceftriaxone was neuroprotective in vitro when used in models of ischaemic injury and motor neuron degeneration, both based in part on glutamate toxicity11. When used in an animal model of the fatal disease ALS, the drug delayed loss of neurons and muscle strength, and increased mouse survival. Thus these studies provide a class of potential neurotherapeutics that act to modulate the expression of glutamate neurotransmitter transporters via gene activation.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Rothstein, J. D. et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16, 675–686 (1996)
    Article CAS Google Scholar
  2. Danbolt, N. C. Glutamate uptake. Prog. Neurobiol. 65, 1–105 (2001)
    Article CAS Google Scholar
  3. Rothstein, J. D., Van Kammen, M., Levey, A. I., Martin, L. J. & Kuncl, R. W. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. 38, 73–84 (1995)
    Article CAS Google Scholar
  4. Rao, V. L. et al. Antisense knockdown of the glial glutamate transporter GLT-1, but not the neuronal glutamate transporter EAAC1, exacerbates transient focal cerebral ischemia-induced neuronal damage in rat brain. J. Neurosci. 21, 1876–1883 (2001)
    Article CAS Google Scholar
  5. Ye, Z. C., Rothstein, J. D. & Sontheimer, H. Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J. Neurosci. 19, 10767–10777 (1999)
    Article CAS Google Scholar
  6. Sepkuty, J. P. et al. A neuronal glutamate transporter contributes to neurotransmitter GABA synthesis and epilepsy. J. Neurosci. 22, 6372–6379 (2002)
    Article CAS Google Scholar
  7. Su, Z. Z. et al. Insights into glutamate transport regulation in human astrocytes: cloning of the promoter for excitatory amino acid transporter 2 (EAAT2). Proc. Natl Acad. Sci. USA 100, 1955–1960 (2003)
    Article ADS CAS Google Scholar
  8. Goodman, L. S., Hardman, J. G., Limbird, L. E. & Gilman, A. G. Goodman & Gilman's The Pharmacological Basis of Therapeutics (McGraw-Hill Medical Pub. Division, New York, 2001)
    Google Scholar
  9. Tanaka, K. et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276, 1699–1702 (1997)
    Article CAS Google Scholar
  10. Watase, K. et al. Motor discoordination and increased susceptibility to cerebellar injury in GLAST mutant mice. Eur. J. Neurosci. 10, 976–988 (1998)
    Article CAS Google Scholar
  11. Rothstein, J. D., Jin, L., Dykes-Hoberg, M. & Kuncl, R. W. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc. Natl Acad. Sci. USA 90, 6591–6595 (1993)
    Article ADS CAS Google Scholar
  12. Chandrasekar, P., Rolston, K., Smith, B. & LeFrock, J. Diffusion of ceftriaxone into the cerebrospinal fluid of adults. J. Antimicrob. Chemother. 14, 427–430 (1984)
    Article CAS Google Scholar
  13. Nau, R. et al. Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges. Antimicrob. Agents Chemother. 37, 1518–1524 (1993)
    Article CAS Google Scholar
  14. Kazragis, R., Dever, L., Jorgensen, J. & Barbour, A. In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites. Antimicrob. Agents Chemother. 38, 2632–2636 (1996)
    Article Google Scholar
  15. Chen, W. et al. Expression of a variant form of the glutamate transporter GLT1 in neuronal cultures and in neurons and astrocytes in the rat brain. J. Neurosci. 22, 2142–2152 (2002)
    Article CAS Google Scholar
  16. Schlag, B. D. et al. Regulation of the glial Na+-dependent glutamate transporters by cyclic AMP analogs and neurons. Mol. Pharmacol. 53, 355–369 (1998)
    Article CAS Google Scholar
  17. Guo, H. et al. Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum. Mol. Genet. 12, 2519–2532 (2003)
    Article CAS Google Scholar
  18. Romera, C. et al. In vitro ischemic tolerance involves upregulation of glutamate transport partly mediated by the TACE/ADAM17-tumor necrosis factor-alpha pathway. J. Neurosci. 24, 1350–1357 (2004)
    Article CAS Google Scholar
  19. Spalloni, A. et al. Cu/Zn-superoxide dismutase (GLY93 → ALA) mutation alters AMPA receptor subunit expression and function and potentiates kainate-mediated toxicity in motor neurons in culture. Neurobiol. Dis. 15, 340–350 (2004)
    Article CAS Google Scholar
  20. Canton, T. et al. RPR 119990, a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis. J. Pharmacol. Exp. Ther. 299, 314–322 (2001)
    CAS PubMed Google Scholar
  21. Rothstein, J. D. & Kuncl, R. W. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J. Neurochem. 65, 643–651 (1995)
    Article CAS Google Scholar
  22. Kaspar, B. K., Llado, J., Sherkat, N., Rothstein, J. D. & Gage, F. H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301, 839–842 (2003)
    Article ADS CAS Google Scholar
  23. Drachman, D. B. et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 52, 771–778 (2002)
    Article CAS Google Scholar
  24. Howland, D. S. et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl Acad. Sci. USA 99, 1604–1609 (2002)
    Article ADS CAS Google Scholar
  25. Rothstein, J. D., Martin, L. J. & Kuncl, R. W. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N. Engl. J. Med. 326, 1464–1468 (1992)
    Article CAS Google Scholar
  26. Gong, S., Yang, X. W., Li, C. & Heintz, N. Highly efficient modification of bacterial artificial chromosomes (BACs) using novel shuttle vectors containing the R6Kgamma origin of replication. Genome Res. 12, 1992–1998 (2002)
    Article CAS Google Scholar

Download references

Acknowledgements

We are grateful to J. Lee and C. Cocci for technical assistance; K. Tanaka for GLT1-null mice; C. Leahy for ALS mouse studies; and J. Heemskerk for initiating the project, discussions and encouragement. G93A SOD1 mice were provided by Project ALS. The work was supported by the NIH, the Muscular Dystrophy Association and The Robert Packard Center for ALS Research at Johns Hopkins.

Author information

Authors and Affiliations

  1. Department of Neurology,
    Jeffrey D. Rothstein, Sarjubhai Patel, Melissa R. Regan, Christine Haenggeli, Lin Jin, Margaret Dykes Hoberg, Svetlana Vidensky, Dorothy S. Chung & Shuy Vang Toan
  2. Department of Neuroscience, Johns Hopkins University, Baltimore, Maryland, 21287, USA
    Jeffrey D. Rothstein, Yanhua H. Huang & Dwight E. Bergles
  3. The ALS Association, USA, Palm Harbor, Florida, 34685
    Lucie I. Bruijn
  4. Department of Pathology, Neurosurgery and Urology, Columbia University Medical Center, College of Physicians and Surgeons, New York, New York, 10032, USA
    Zao-zhong Su, Pankaj Gupta & Paul B. Fisher

Authors

  1. Jeffrey D. Rothstein
    You can also search for this author inPubMed Google Scholar
  2. Sarjubhai Patel
    You can also search for this author inPubMed Google Scholar
  3. Melissa R. Regan
    You can also search for this author inPubMed Google Scholar
  4. Christine Haenggeli
    You can also search for this author inPubMed Google Scholar
  5. Yanhua H. Huang
    You can also search for this author inPubMed Google Scholar
  6. Dwight E. Bergles
    You can also search for this author inPubMed Google Scholar
  7. Lin Jin
    You can also search for this author inPubMed Google Scholar
  8. Margaret Dykes Hoberg
    You can also search for this author inPubMed Google Scholar
  9. Svetlana Vidensky
    You can also search for this author inPubMed Google Scholar
  10. Dorothy S. Chung
    You can also search for this author inPubMed Google Scholar
  11. Shuy Vang Toan
    You can also search for this author inPubMed Google Scholar
  12. Lucie I. Bruijn
    You can also search for this author inPubMed Google Scholar
  13. Zao-zhong Su
    You can also search for this author inPubMed Google Scholar
  14. Pankaj Gupta
    You can also search for this author inPubMed Google Scholar
  15. Paul B. Fisher
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toJeffrey D. Rothstein.

Ethics declarations

Competing interests

Under a licensing agreement between Ruxton Pharmaceuticals, Inc. and the Johns Hopkins University, J.D.R. is entitled to a share of royalty received by the University on sales of products described in this study. J.D.R. and the University own Ruxton Pharmaceuticals, Inc. stock, which is subject to certain restrictions under University policy. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.

Supplementary information

Supplementary Notes

This file contains Supplementary Methods, Supplementary Data and additional references. (DOC 66 kb)

Rights and permissions

About this article

Cite this article

Rothstein, J., Patel, S., Regan, M. et al. β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.Nature 433, 73–77 (2005). https://doi.org/10.1038/nature03180

Download citation

This article is cited by

Editorial Summary

Rewrite the pharmacopoeia

The β-lactam antibiotics — penicillin and its semisynthetic derivatives — act by inhibiting bacterial synthetic pathways, and their success has in part been because they have little effect on their hosts. So it's a complete surprise to find that many of these β-lactams also act on the dominant excitatory neurotransmitter transporter system in the mammalian central nervous system. The mechanism of action involves activation of GLT1, the gene for glutamate transport. In animal models of ischaemic injury and motor neuron degeneration, ceftriaxone is neuroprotective, and in the animal model of the fatal disease amyotrophic lateral sclerosis (Lou Gehrig's disease), it increases the survival rate of mice. These studies provide a completely new drug target for scores of highly safe pharmaceuticals and may lead to new therapies for neurological disease.